Numab signs licensing deal with Chinese biopharmaceutical company

 

CStone and Numab announce an exclusive regional licensing agreement for ND021, a multi-functional drug candidate and potential next-generation immunotherapy. In preclinical models, ND021 was well tolerated and induced exquisite antitumoral effects. Its molecular architecture and binding properties endow ND021 with several advantageous features that may translate into significant clinical benefit in a broad population of cancer patients.

 

Pursuant to the terms of the licensing agreement, CStone will fund the research and development of ND021 up to completion of an initial Phase Ib clinical trial. In exchange, CStone obtains exclusive rights from Numab to develop and commercialize ND021 in Greater China (including Mainland China, Hong Kong, Macau and Taiwan), South Korea and Singapore. Numab retains all ND021 rights for the rest of the world. Upon completion of CStone’s funding period, no further financial obligations will be owed by either party. This collaboration provides CStone with its first access to Numab’s novel multi-specific technology platform and Numab the opportunity to bring this innovative drug candidate into this region. Discovered and engineered using Numab’s proprietary λcap technology and MATCH platform, ND021 is a late-preclinical-stage antibody-based molecule that simultaneously targets PD-L1, 4-1BB, and HSA. In preclinical models, ND021 was well tolerated and induced exquisite antitumoral effects. Its unique, rationally designed molecular architecture and binding properties endow ND021 with several advantageous features that may translate into significant clinical benefit in a broad population of cancer patients. CStone Pharmaceuticals, based in Suzhou (China) is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicine to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline with a strategic emphasis on immune-oncology combination therapies. Currently, 4 late-stage candidates are at or near pivotal trials. With an experienced team, a rich pipeline, a robust clinical development-driven business model, and substantial funding. (Press release)Picture: City of Suzhou (Pixabay)